» Articles » PMID: 30097809

Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management

Overview
Publisher Springer
Specialty Biotechnology
Date 2018 Aug 12
PMID 30097809
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Nanomaterials (NMs) are receiving remarkable attention due to their unique properties and structure. They vary from atoms and molecules along with those of bulk materials. They can be engineered to act as drug delivery vehicles to cross blood-brain barriers (BBBs) and utilized with better efficacy and safety to deliver specific molecules into targeted cells as compared to conventional system for neurological disorders. Depending on their properties, various metal chelators, gold nanoparticles (NPs), micelles, quantum dots, polymeric NPs, liposomes, solid lipid NPs, microparticles, carbon nanotubes, and fullerenes have been utilized for various purposes including the improvement of drug delivery system, treatment response assessment, diagnosis at early stage, and management of neurological disorder by using neuro-engineering. BBB regulates micro- and macromolecule penetration/movement, thus protecting it from many kinds of illness. This phenomenon also prevents drug delivery for the neurological disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis, and primary brain tumors. For some neurological disorders (AD and PD), the environmental pollution was considered as a major cause, as observed that metal and/or metal oxide from different sources are inhaled and get deposited in the lungs/brain. Old age, obesity, diabetes, and cardiovascular disease are other factors for rapid deterioration of human health and onset of AD. In addition, gene mutations have also been examined to cause the early onset familial forms of AD. AD leads to cognitive impairment and plaque deposits in the brain leading to neuronal cell death. Based on these facts and considerations, this review elucidates the importance of frequently used metal chelators, NMs and/or NPs. The present review also discusses the current status and future challenges in terms of their application in drug delivery for neurological disease management.

Citing Articles

Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.

Dhariwal R, Jain M, Mir Y, Singh A, Jain B, Kumar P Front Med (Lausanne). 2025; 12:1522223.

PMID: 39963432 PMC: 11831571. DOI: 10.3389/fmed.2025.1522223.


Advances in Alzheimer's disease control approaches via carbon nanotubes.

Cai J, Li B, Zhang J, Feng G, Liu Y, Fan H Nanomedicine (Lond). 2024; 20(1):63-77.

PMID: 39607021 PMC: 11703444. DOI: 10.1080/17435889.2024.2432855.


Emerging Promise of Green Synthesized Metallic Nanoparticles for the Management of Neurological Disorders.

Moghaddam Z, Esmaili Moghadam Z, Hamidi S, Azarfarin M, Salatin S Curr Pharm Des. 2024; 31(5):344-359.

PMID: 39400023 DOI: 10.2174/0113816128337464240930042205.


Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.

Lopez-Espinosa J, Park P, Holcomb M, Godin B, Villapol S Ther Deliv. 2024; 15(12):997-1024.

PMID: 39297726 PMC: 11583628. DOI: 10.1080/20415990.2024.2401307.


Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A NovelApproach to Diagnosis and Treatment.

Khan J, Yadav S Pharm Nanotechnol. 2023; 12(4):314-328.

PMID: 37818558 DOI: 10.2174/0122117385265554230919070402.


References
1.
Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

2.
Adlard P, Bush A . Metals and Alzheimer's disease. J Alzheimers Dis. 2006; 10(2-3):145-63. DOI: 10.3233/jad-2006-102-303. View

3.
Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F . Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012; 72(4):610-24. DOI: 10.1002/ana.23627. View

4.
Beduneau A, Saulnier P, Benoit J . Active targeting of brain tumors using nanocarriers. Biomaterials. 2007; 28(33):4947-67. DOI: 10.1016/j.biomaterials.2007.06.011. View

5.
Liu G, Men P, Kudo W, Perry G, Smith M . Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett. 2009; 455(3):187-90. PMC: 2683427. DOI: 10.1016/j.neulet.2009.03.064. View